Managing Intellectual Property (MIP) has named Gowling WLG the Canadian “Patent Contentious Firm of the Year” at the MIP Americas Awards 2022. Last night, Ottawa partner Christopher Van Barr, who was nominated… Read More
Orally bioavailable ANITAC™ degraders can eliminate full length, mutant and splice variant forms of AR that are expressed in castration-resistant prostate cancer (CRPC) patients ANITAC degraders inhibit AR-dependent transcription and reduce… Read More
VANCOUVER, BC — AbCellera (Nasdaq: ABCL), a technology company focused on next-generation antibody discovery, today announced the release of data on its new T cell engager platform at the American Association… Read More
Bold Therapeutics is excited to share further information elucidating the mechanism-of-action of BOLD-100 and demonstrating its unique potential as an anticancer agent. Read more here.
At the 2022 Roth Conference in California, InMed’s CEO, Eric A. Adams, sat down with Roth Capital Analyst Scott R. Henry in a fireside chat. During their discussion, Eric talks… Read More
